GEN Exclusives

More »

GEN News Highlights

More »
Mar 28, 2008

Aerovance Closes $10M Financing Round

  • Aerovance secured $20 million in venture debt financing. Aerovance says that it drew down $10 million from the financing line at closing. The remaining $10 million is available upon the achievement of corporate milestones.

    The money will support development of Aerovant, which is in Phase IIa studies for asthma. Aerovant is a recombinant human IL-4 variant that is an inhibitor of both the IL-4 and IL-13 receptors.

    Oxford Finance Corporation led the syndicate, which includes Silicon Valley Bank and Comerica Bank.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »